For patients with mantle cell lymphoma (MCL), achieving event-free survival at 24 months (EFS24) using modern treatments was associated with improved overall survival (OS) and lymphoma-related mortality was no longer the leading cause of death, according to a study presented at the Eleventh Annual Meeting of the Society of Hematologic Oncology.
Yucai Wang, MD, PhD, of Mayo Clinic in Rochester, Minnesota, and colleagues presented a poster detailing their evaluation of conditional survival and cause of death after achieving EFS24 in patients with MCL.
Their study included cohorts of patients from the Mayo Clinic/Iowa MER, BC Cancer, and Swedish Lymphoma Register. The researchers defined two treatment eras for each cohort based on local treatment pattern changes.
In the MER cohort, 110 patients were treated in Era M1 from 2002-2009 and 127 patients in M2 from 2010-2015. Both groups had inferior survival compared with the general population of the United States. Lymphoma was the leading cause of death in both eras. Patients in Era M1 who achieved EFS24 had inferior OS compared with the general population (standard mortality rate [SMR]=2.81). However, in Era M2, patients achieving EFS24 had a similar OS compared with the general population (SMR=1.35), and lymphoma was not the leading cause of death.
In the BC Cancer Cohort, the 188 patients treated in Era B2 (2013-2019) versus Era B1 (2003-2013) had a narrower OS gap compared with the British Columbia general population (SMR 4.53 vs 6.69). For patients achieving EFS24, the OS gap was narrower for Era B2 compared with Era B1 (SMR 3.56 vs 4.99). After achieving EFS24, lymphoma was no longer the leading cause of death for Era B2.
Similarly, the gap in OS was narrower for patients in the Swedish cohort Era S2 (2013-2018) versus Era S1 (2006-2012). Lymphoma was no longer the leading cause of death for patients achieving EFS24 in Era S2.
Yang Y, Larson M, Ekberg S, et al. Multicohort study of conditional survival and cause of death after achieving event-free survival at 24 Months (EFS24) in patients with mantle cell lymphoma (MCL). Abstract MCL-063. Presented at the Eleventh Annual Meeting of the Society of Hematologic Oncology; September 6-9, 2023; Houston, Texas.